
  
    
      
        Introduction_NNP
        Enumeration_NNP of_IN peripheral_JJ blood_NN (_( PB_NNP )_) leukemic_JJ cells_NNS in_IN
        mycosis_NNS fungoides_NNS (_( MF_NNP )_) /_NN Sézary_NNP syndrome_NN (_( SS_NNP )_) can_MD be_VB
        difficult_JJ by_IN morphological_JJ methods_NNS ._. This_DT is_VBZ due_JJ to_TO
        difficulties_NNS in_IN unequivocally_RB distinguishing_VBG neoplastic_JJ
        cells_NNS from_IN reactive_JJ lymphocytes_NNS on_IN standard_JJ
        Wright-_NNP Giemsa-stained_NNP PB_NNP smears_NNS ._. Electron_NNP microscopic_JJ
        evaluation_NN of_IN blood_NN samples_NNS is_VBZ impractical_JJ for_IN routine_JJ use_NN ._.
        Therefore_RB ,_, most_JJS centers_NNS have_VBP relied_VBN on_IN flow_NN cytometric_JJ
        evaluation_NN of_IN such_JJ specimens_NNS ._.
        Flow_NNP cytometric_JJ abnormalities_NNS in_IN MF_NNP /_NN SS_NNP that_WDT have_VBP been_VBN
        correlated_JJ with_IN the_DT presence_NN of_IN tumor_NN cells_NNS include_VBP
        increased_VBN populations_NNS of_IN CD_NNP 4_CD -_: positive_NN and_CC /_NN or_CC CD_NNP 7_CD -_: negative_JJ
        T-_NNP cells_NNS ._. [_NN 1_CD 2_CD 3_CD ]_NN We_PRP have_VBP recently_RB shown_VBN that_IN increases_NNS in_IN
        CD_NNP 4_CD -_: positive_JJ ,_, CD_NNP 26_CD -_: negative_JJ T-_NNP cell_NN populations_NNS are_VBP highly_RB
        associated_VBN with_IN the_DT presence_NN of_IN tumor_NN cells_NNS in_IN MF_NNP /_NN SS_NNP [_NN 4_CD ]_NN
        ._.
        Another_DT approach_NN to_TO flow_VB cytometric_JJ detection_NN of_IN tumor_NN
        cells_NNS has_VBZ been_VBN the_DT identification_NN of_IN phenotypically_RB
        aberrant_NN populations_NNS that_WDT express_VBP different_JJ amounts_NNS of_IN cell_NN
        surface_NN proteins_NNS than_IN normal_JJ T-_NNP cell_NN populations_NNS ._. Such_JJ
        stable_JJ abnormal_JJ expression_NN levels_NNS of_IN pan-_NN T_NN cell_NN markers_NNS is_VBZ
        a_DT common_JJ feature_NN of_IN T_NN cell_NN tumors_NNS [_NN 5_CD ]_NN ._. We_PRP sought_VBD to_TO
        identify_VB the_DT frequency_NN of_IN such_JJ abnormalities_NNS in_IN MF_NNP /_NN SS_NNP in_IN PB_NNP
        and_CC to_TO determine_VB whether_IN these_DT immunophenotypic_JJ aberrancies_NNS
        are_VBP stable_JJ over_IN the_DT course_NN of_IN treatment_NN ._. We_PRP report_VBP that_IN
        alterations_NNS in_IN expression_NN of_IN multiple_JJ T_NN cell_NN markers_NNS as_IN
        detected_VBN by_IN flow_NN cytometry_NN are_VBP an_DT easily_RB identifiable_JJ and_CC
        stable_JJ feature_NN of_IN nearly_RB all_DT cases_NNS of_IN MF_NNP /_NN SS_NNP ._. Such_JJ
        immunophenotypic_JJ aberrancies_NNS can_MD be_VB used_VBN to_TO quantify_VB tumor_NN
        cells_NNS from_IN a_DT patient_NN over_IN the_DT course_NN of_IN the_DT disease_NN ._.
      
      
        Methods_NNP
        
          Patient_NNP samples_NNS
          We_PRP screened_VBD all_DT PB_NNP smears_NNS from_IN patients_NNS referred_VBD to_TO
          our_PRP$ hospital_NN between_IN January_NNP 1999_CD and_CC June_NNP 2002_CD who_WP had_VBD a_DT
          diagnosis_NN of_IN cutaneous_JJ atypical_JJ lymphoid_NN infiltrate_VB ,_, MF_NNP ,_,
          or_CC SS_NNP and_CC a_DT had_VBD a_DT full_JJ PB_NNP flow_NN cytometry_NN panel_NN ._. Cases_NNS
          were_VBD considered_VBN morphologically_RB positive_JJ if_IN they_PRP
          contained_VBD at_IN least_JJS 1_CD %_NN tumor_NN cells_NNS by_IN manual_JJ differential_NN ._.
          We_PRP also_RB included_VBD subsequent_JJ involved_VBN PB_NNP samples_NNS from_IN
          these_DT patients_NNS ._. Most_JJS of_IN the_DT PB_NNP smears_NNS were_VBD reviewed_VBN by_IN a_DT
          single_JJ hematopathologist_NN (_( DJ_NNP )_) to_TO ensure_VB relatively_RB
          uniform_NN criteria_NNS in_IN counting_NN of_IN tumor_NN cells_NNS ._. Sézary_NNP tumor_NN
          cells_NNS were_VBD defined_VBN as_IN either_DT those_DT with_IN markedly_RB
          convoluted_JJ nuclear_JJ contours_NNS or_CC those_DT that_WDT were_VBD enlarged_JJ
          and_CC had_VBD prominent_JJ nucleoli_NN ._. Diagnoses_NNP were_VBD based_VBN on_IN
          criteria_NNS outlined_VBN in_IN the_DT updated_VBN World_NNP Health_NNP
          Organization_NNP classification_NN [_NN 6_CD ]_NN ._. Patients_NNPS were_VBD
          diagnosed_VBN to_TO have_VB MF_NNP if_IN PB_NNP involvement_NN occurred_VBD
          subsequent_JJ to_TO patch_VB /_NN plaque_NN cutaneous_JJ T-_NNP cell_NN lymphoma_NN or_CC
          SS_NNP if_IN the_DT presenting_VBG features_NNS included_VBD an_DT erythrodermic_JJ
          rash_NN with_IN >_NN 500_CD /_NN μL_NN PB_NNP tumor_NN cells_NNS ._.
          All_DT studies_NNS were_VBD carried_VBN out_IN in_IN accordance_NN with_IN the_DT
          Declaration_NNP of_IN Helsinki_NNP and_CC followed_VBD a_DT laboratory_NN
          protocol_NN approved_VBN by_IN our_PRP$ institutional_JJ review_NN board_NN ._.
        
        
          Flow_NNP cytometry_NN
          We_PRP utilized_JJ a_DT standard_JJ T-_NNP cell_NN antigen_NN panel_NN to_TO analyze_VB
          the_DT 100_CD PB_NNP samples_NNS from_IN the_DT 44_CD patients_NNS ._. 2_LS -_: ,_, 3_CD -_: or_CC
          4_CD -_: color_NN flow_NN cytometric_JJ analysis_NN was_VBD performed_VBN on_IN all_DT
          samples_NNS following_VBG a_DT standard_JJ red_JJ cell_NN lysis_NNS method_NN using_VBG
          mouse_NN monoclonal_NN antibodies_NNS directed_VBN against_IN CD_NNP 45_CD (_( clone_NN
          2_CD D_NNP 1_CD ,_, peridin-chlorophyll-a-protein_JJ [_NN PerCP_NNP ]_NN -_: conjugated_JJ ,_, )_)
          as_RB well_RB as_IN various_JJ combinations_NNS of_IN CD_NNP 26_CD (_( fluorescien_NN
          isothiocyanate_NN [_NN FITC_NNP ]_NN -_: conjugated_JJ )_) ,_, CD_NNP 3_CD (_( SK_NNP 7_CD ,_, FITC_NNP or_CC
          phycoerythrin_NN [_NN PE_NNP ]_NN )_) ,_, CD_NNP 4_CD (_( SK_NNP 3_CD ,_, PE_NNP )_) ,_, CD_NNP 7_CD (_( 4_CD H_NNP 9_CD ,_, FITC_NNP )_) ,_, CD_NNP 8_CD
          (_( SK_NNP 1_CD ,_, FITC_NNP or_CC PE_NNP )_) ,_, CD_NNP 19_CD (_( SJ_NNP 25_CD C_NNP 1_CD ,_, FITC_NNP )_) and_CC CD_NNP 26_CD (_( L_NNP 272_CD ,_,
          FITC_NNP )_) ._. In_IN addition_NN ,_, CD_NNP 2_CD (_( S_NNP 5_CD ._. 2_LS ,_, FITC_NNP )_) ,_, CD_NNP 5_CD (_( L_NNP 17_CD F_NN 12_CD ,_, PE_NNP )_) ,_,
          and_CC αβ_NN T-_NNP cell_NN receptor_NN (_( T_NN 10_CD B_NNP 9_CD ,_, FITC_NNP or_CC PE_NNP )_) were_VBD done_VBN ,_, in_IN
          a_DT subset_NN of_IN cases_NNS ._. All_DT antibodies_NNS were_VBD from_IN BD_NNP
          Biosciences_NNP ,_, San_NNP Jose_NNP ,_, CA_NNP and_CC analysis_NN was_VBD performed_VBN
          using_VBG FACScan_NNP or_CC FACScaliber_NNP cytometers_NNS (_( BD_NNP )_) ._.
          For_IN each_DT antibody_NN ,_, negative_JJ staining_VBG levels_NNS were_VBD set_VBN
          by_IN comparison_NN to_TO an_DT isotype-matched_JJ control_NN ._. In_IN a_DT subset_NN
          of_IN 23_CD cases_NNS ,_, cluster_NN analysis_NN using_VBG Paint-a-gate_NNP
          ®_NN software_NN (_( BD_NNP )_) was_VBD done_VBN to_TO correlate_VBP the_DT size_NN of_IN the_DT
          different_JJ lymphocyte_NN populations_NNS with_IN the_DT phenotypically_RB
          aberrant_NN T-_NNP cell_NN clusters_NNS ._. Aberrant_NNP T_NN cell_NN populations_NNS
          were_VBD defined_VBN as_IN discrete_JJ immunophenotypic_JJ clusters_NNS
          (_( representing_VBG a_DT tight_JJ cluster_NN of_IN 0_CD ._. 5_CD %_NN or_CC more_RBR of_IN analyzed_VBD
          events_NNS )_) exhibiting_VBG change_NN in_IN levels_NNS of_IN expression_NN of_IN
          T-_NNP cell_NN antigens_NNS relative_JJ to_TO an_DT internal_JJ
          immunophenotypically_RB normal_JJ T-_NNP cell_NN population_NN or_CC relative_JJ
          to_TO expected_VB expression_NN of_IN T_NN cell_NN associated_VBN antigens_NNS ._. As_IN
          a_DT control_NN group_NN for_IN variations_NNS in_IN T-_NNP cell_NN markers_NNS in_IN
          non-neoplastic_JJ T-_NNP cell_NN populations_NNS ,_, we_PRP used_VBD the_DT flow_NN
          cytometry_NN results_NNS from_IN 100_CD patients_NNS with_IN MF_NNP or_CC cutaneous_JJ
          atypical_JJ T-_NNP cell_NN infiltrates_NNS whose_WP$ PB_NNP smears_NNS did_VBD not_RB show_VB
          identifiable_JJ tumor_NN cells_NNS ,_, and_CC 10_CD samples_NNS from_IN control_NN
          patients_NNS without_IN any_DT evidence_NN of_IN malignancy_NN or_CC chronic_JJ
          disease_NN ._. The_DT details_NNS of_IN these_DT PB_NNP cases_NNS were_VBD previously_RB
          summarized_VBD [_NN 4_CD ]_NN ._. We_PRP have_VBP previously_RB shown_VBN high_JJ levels_NNS
          of_IN correlation_NN between_IN the_DT presence_NN of_IN an_DT abnormal_JJ T-_NNP cell_NN
          population_NN identified_VBN by_IN this_DT flow_NN cytometry_NN panel_NN and_CC
          the_DT presence_NN of_IN morphologically_RB identifiable_JJ tumor_NN cells_NNS
          on_IN examination_NN of_IN the_DT smear_NN [_NN 4_CD ]_NN ._.
          The_DT Kruskal-_NNP Wallis_NNP test_NN and_CC Spearman_NNP 's_POS rank_NN
          correlation_NN test_NN were_VBD used_VBN to_TO compare_VB the_DT association_NN of_IN
          phenotypic_JJ aberrancy_NN between_IN different_JJ markers_NNS ._.
          Statistical_NNP significance_NN was_VBD defined_VBN as_IN α_NN =_SYM 0_CD ._. 05_CD ._.
        
      
      
        Results_NNS
        
          Immunophenotypic_NNP aberrancy_NN of_IN common_JJ T-_NNP cell_NN markers_NNS
          is_VBZ present_JJ in_IN nearly_RB all_DT cases_NNS of_IN MF_NNP /_NN SS_NNP
          In_IN 41_CD of_IN 44_CD MF_NNP /_NN SS_NNP patients_NNS (_( 93_CD %_NN )_) ,_, there_EX was_VBD a_DT discrete_JJ
          phenotypically_RB abnormal_JJ population_NN (_( s_VBZ )_) identified_VBN by_IN flow_NN
          cytometric_JJ analysis_NN that_IN correlated_JJ with_IN the_DT presence_NN of_IN
          morphologically_RB identifiable_JJ tumor_NN cells_NNS on_IN PB_NNP smear_NN ._. In_IN
          a_DT group_NN of_IN 100_CD SS_NNP /_NN MF_NNP patients_NNS with_IN morphologically_RB 
          uninvolved_JJ PB_NNP smears_NNS ,_, flow_NN
          cytometric_JJ analysis_NN identified_VBD a_DT phenotypically_RB abnormal_JJ
          CD_NNP 4_CD +_NN T-_NNP cell_NN population_NN in_IN only_RB 2_CD cases_NNS ._. These_DT abnormal_JJ
          populations_NNS ,_, detected_VBD only_RB by_IN flow_NN cytometry_NN ,_, comprised_VBN 1_CD
          and_CC 2_CD %_NN of_IN total_JJ white_JJ blood_NN cells_NNS and_CC were_VBD discrete_JJ
          CD_NNP 4_CD -_: dim_NN CD_NNP 26_CD -_: negative_JJ T-_NNP cell_NN populations_NNS ._. Rereview_NNP of_IN PB_NNP
          smears_NNS from_IN these_DT patients_NNS ,_, who_WP had_VBD typical_JJ cutaneous_JJ
          findings_NNS of_IN MF_NNP ,_, did_VBD not_RB identify_VB definitive_JJ Sezary_NNP cells_NNS ._.
          The_DT CD_NNP 4_CD /_NN CD_NNP 8_CD ratio_NN was_VBD elevated_VBD (_( >_NN 4_CD :_: 1_LS )_) in_IN 77_CD %_NN of_IN the_DT
          involved_VBN PB_NNP samples_NNS ,_, at_IN presentation_NN ,_, and_CC in_IN 74_CD %_NN of_IN the_DT
          followup_NN involved_VBD PB_NNP samples_NNS but_CC in_IN only_RB 13_CD %_NN of_IN the_DT PB_NNP
          samples_NNS from_IN MF_NNP /_NN SS_NNP patients_NNS without_IN tumor_NN cells_NNS seen_VBN on_IN
          smear_NN ._. No_DT flow_NN cytometric_JJ abnormalities_NNS were_VBD detected_VBN in_IN
          CD_NNP 4_CD -_: positive_JJ T-_NNP cells_NNS from_IN 10_CD control_NN patients_NNS without_IN
          lymphoproliferative_JJ disorders_NNS ._.
          The_DT overall_JJ incidence_NN of_IN different_JJ immunophenotypic_JJ
          aberrancies_NNS among_IN the_DT 44_CD MF_NNP /_NN SS_NNP patients_NNS is_VBZ summarized_VBD in_IN
          Table_NNP 1_CD ._. We_PRP noted_VBD abnormal_JJ expression_NN levels_NNS of_IN CD_NNP 3_CD by_IN
          flow_NN cytometry_NN in_IN 34_CD %_NN of_IN patients_NNS ;_: tumor_NN cells_NNS were_VBD
          dimmer_NN for_IN CD_NNP 3_CD than_IN normal_JJ T-_NNP cell_NN levels_NNS in_IN 11_CD patients_NNS ,_,
          brighter_JJR than_IN normal_JJ for_IN CD_NNP 3_CD in_IN 2_CD patients_NNS (_( Fig_NNP ._. 1_LS A_DT )_) and_CC
          completely_RB negative_JJ for_IN CD_NNP 3_CD in_IN 2_CD patients_NNS ._. Similarly_RB ,_,
          abnormal_JJ levels_NNS of_IN CD_NNP 4_CD expression_NN were_VBD seen_VBN in_IN 24_CD (_( 54_CD %_NN )_)
          patients_NNS (_( 21_CD dimmer_NN ,_, 1_CD brighter_JJR ,_, 2_CD negative_JJ )_) (_( Fig_NNP ._. 1_LS B_NNP )_) ._.
          Coexpression_NNP of_IN CD_NNP 4_CD and_CC CD_NNP 8_CD was_VBD seen_VBN in_IN tumor_NN cells_NNS from_IN
          2_CD patients_NNS ._. In_IN 17_CD %_NN of_IN patients_NNS ,_, tumor_NN cells_NNS showed_VBD both_DT
          CD_NNP 3_CD and_CC CD_NNP 4_CD aberrancies_NNS ,_, however_RB the_DT magnitude_NN of_IN these_DT
          changes_NNS were_VBD not_RB highly_RB correlated_JJ when_WRB graded_JJ as_IN
          negative_JJ (_( 0_CD )_) ,_, dim_NN (_( 1_LS )_) ,_, normal_JJ (_( 2_LS )_) or_CC bright_JJ (_( 3_LS )_) (_( R_NN value_NN
          =_SYM ._. 23_CD )_) ._.
          In_IN a_DT subset_NN of_IN cases_NNS tested_VBN ,_, abnormalities_NNS in_IN the_DT
          dimmer_NN expression_NN level_NN of_IN CD_NNP 45_CD were_VBD seen_VBN in_IN 4_CD of_IN 10_CD
          (_( 40_CD %_NN )_) cases_NNS (_( Fig_NNP ._. 1_LS A_DT )_) ._. T-_NNP cell_NN receptor-alpha_JJ /_NN beta_NN
          (_( TCR-α_NNP /_NN β_NN )_) expression_NN levels_NNS were_VBD determined_VBN in_IN 19_CD cases_NNS
          and_CC was_VBD 100_CD %_NN correlated_JJ with_IN CD_NNP 3_CD expression_NN ,_, in_IN that_DT dim_NN
          TCR-α_NNP /_NN β_NN expression_NN in_IN 3_CD cases_NNS was_VBD associated_VBN with_IN dim_NN CD_NNP 3_CD
          and_CC TCR-α_NNP /_NN β_NN was_VBD negative_JJ in_IN the_DT 2_CD cases_NNS that_WDT showed_VBD
          absence_NN of_IN surface_NN CD_NNP 3_CD ._. CD_NNP 5_CD expression_NN was_VBD abnormal_JJ in_IN 5_CD
          of_IN 20_CD (_( 25_CD %_NN )_) ,_, of_IN tested_VBN cases_NNS (_( dimmer_NN in_IN 4_CD ,_, brighter_JJR in_IN 1_LS )_) ,_,
          by_IN standard_JJ analysis_NN ._. However_RB ,_, the_DT level_NN of_IN CD_NNP 5_CD
          expression_NN in_IN T-_NNP cells_NNS was_VBD typically_RB variable_JJ and_CC careful_JJ
          cluster_NN analysis_NN in_IN 5_CD additional_JJ cases_NNS identified_VBD
          discrete_JJ CD_NNP 5_CD -_: dim_NN tumor_NN cell_NN populations_NNS ._.
          T-_NNP cells_NNS in_IN normal_JJ PB_NNP typically_RB showed_VBD a_DT continuous_JJ
          variation_NN in_IN CD_NNP 7_CD expression_NN level_NN ._. In_IN involved_VBN MF_NNP /_NN SS_NNP PB_NNP
          samples_NNS ,_, tumor_NN cells_NNS were_VBD uniformly_RB negative_JJ in_IN 17_CD
          patients_NNS (_( 39_CD %_NN )_) and_CC uniformly_RB positive_JJ in_IN 10_CD patients_NNS
          (_( 23_CD %_NN )_) ._. In_IN the_DT remaining_VBG 17_CD patients_NNS (_( 38_CD %_NN )_) ,_, CD_NNP 7_CD expression_NN
          in_IN tumor_NN was_VBD variable_JJ (_( Fig_NNP ._. 1_LS B_NNP )_) and_CC was_VBD often_RB
          indistinguishable_JJ from_IN the_DT range_NN of_IN expression_NN seen_VBN in_IN
          normal_JJ T-_NNP cells_NNS ._. The_DT T-_NNP cell_NN activation_NN marker_NN CD_NNP 26_CD was_VBD
          uniformly_RB negative_JJ in_IN tumor_NN cells_NNS from_IN 36_CD patients_NNS (_( 81_CD %_NN )_) ,_,
          uniformly_RB positive_JJ in_IN 2_CD patients_NNS and_CC showed_VBD variable_JJ
          positivity_NN in_IN 6_CD ._. Thus_RB ,_, in_IN 38_CD of_IN 44_CD (_( 86_CD %_NN )_) patients_NNS ,_,
          CD_NNP 4_CD /_NN CD_NNP 26_CD and_CC CD_NNP 3_CD /_NN CD_NNP 26_CD histograms_NNS clearly_RB separated_JJ the_DT
          phenotypically_RB atypical_JJ T-_NNP cell_NN populations_NNS (_( Figs_NNP ._. 1_LS Cand_NNP
          2_LS )_) ._.
        
        
          Multiple_NNP phenotypically_RB aberrant_NN T-_NNP cell_NN populations_NNS
          in_IN MF_NNP /_NN SS_NNP
          In_IN 5_CD patients_NNS with_IN long_JJ standing_NN MF_NNP ,_, we_PRP noted_VBD 2_CD
          discrete_JJ phenotypically_RB abnormal_JJ T-_NNP cell_NN populations_NNS in_IN
          PB_NNP ._. In_IN 2_CD patients_NNS ,_, these_DT included_VBD a_DT CD_NNP 3_CD -_: dim_NN population_NN
          (_( Fig_NNP ._. 3_LS A_DT )_) ;_: in_IN 2_CD other_JJ patients_NNS there_EX were_VBD CD_NNP 4_CD -_: dim_NN and_CC
          CD_NNP 4_CD -_: negative_JJ populations_NNS (_( Fig_NNP ._. 3_LS B_NNP /_NN 3_CD C_NNP )_) ._. The_DT remaining_VBG
          patient_NN had_VBD two_CD discrete_JJ populations_NNS detected_VBN by_IN CD_NNP 45_CD and_CC
          CD_NNP 5_CD staining_VBG ._. In_IN 4_CD cases_NNS ,_, cluster_NN analysis_NN correlated_JJ the_DT
          different_JJ phenotypically_RB aberrant_NN populations_NNS with_IN the_DT
          normal-sized_JJ and_CC large_RB transformed_VBN neoplastic_JJ T-_NNP cell_NN
          populations_NNS seen_VBN on_IN PB_NNP smear_NN ._. This_DT was_VBD done_VBN by_IN
          pseudocoloring_VBG the_DT abnormal_JJ cell_NN cluster_NN in_IN the_DT various_JJ
          antibody_NN panels_NNS and_CC correlating_VBG the_DT relative_JJ cell_NN size_NN of_IN
          these_DT clusters_NNS on_IN the_DT forward_JJ /_NN side_NN scatter_NN histograms_NNS
          (_( Fig_NNP ._. 3_LS A_DT /_NN 3_CD C_NNP )_) ._.
        
        
          Phenotypic_NNP aberrancies_NNS in_IN T-_NNP cells_NNS are_VBP stable_JJ over_IN
          the_DT course_NN of_IN disease_NN
          In_IN 38_CD of_IN the_DT patients_NNS ,_, we_PRP analyzed_VBD followup_NN PB_NNP samples_NNS
          that_WDT had_VBD tumor_NN cells_NNS identified_VBN on_IN smear_NN and_CC a_DT
          phenotypically_RB abnormal_JJ population_NN identified_VBN by_IN flow_NN
          cytometry_NN ._. We_PRP examined_VBD from_IN 2_CD to_TO 8_CD different_JJ samples_NNS from_IN
          these_DT patients_NNS over_IN the_DT 3_CD -_: year_NN study_NN period_NN ._. In_IN a_DT subset_NN
          of_IN cases_NNS ,_, we_PRP used_VBD the_DT Paint-a-gate_NNP software_NN (_( on_IN the_DT
          forward-side_JJ scatter_NN and_CC other_JJ histograms_NNS )_) to_TO quantify_VB
          the_DT size_NN of_IN the_DT aberrant_NN (_( tumor_NN cell_NN )_) T-_NNP cell_NN population_NN
          in_IN comparison_NN with_IN the_DT other_JJ white_JJ blood_NN cell_NN types_NNS
          detected_VBD ._. As_IN shown_VBN in_IN Table_NNP 2_CD ,_, such_JJ a_DT technique_NN could_MD be_VB
          used_VBN to_TO document_VB oscillations_NNS in_IN tumor_NN cell_NN number_NN that_WDT
          occurred_VBD over_IN the_DT course_NN of_IN treatment_NN ._.
          In_IN 36_CD of_IN 38_CD patients_NNS ,_, phenotypic_JJ aberrancies_NNS in_IN the_DT
          levels_NNS of_IN CD_NNP 3_CD ,_, CD_NNP 4_CD and_CC CD_NNP 26_CD were_VBD stable_JJ with_IN similar_JJ
          expression_NN levels_NNS detected_VBD in_IN all_DT involved_VBN PB_NNP samples_NNS ._. In_IN
          contrast_NN ,_, CD_NNP 7_CD expression_NN varied_VBD in_IN the_DT aberrant_NN tumor_NN
          cell_NN population_NN in_IN 10_CD of_IN 38_CD (_( 26_CD %_NN )_) cases_NNS ._. Fig_NNP ._. 4_LS shows_VBZ a_DT
          patient_NN with_IN CD_NNP 4_CD -_: dim_NN phenotypic_JJ aberrancy_NN in_IN tumor_NN cells_NNS
          that_WDT remained_VBD constant_JJ over_IN the_DT course_NN of_IN disease_NN ._. In_IN
          this_DT patient_NN ,_, intervening_VBG treatments_NNS with_IN Targretin_NNP ,_,
          interferon_NN ,_, and_CC photopheresis_NNS had_VBD no_DT discernible_JJ effect_NN
          on_IN overall_JJ PB_NNP tumor_NN cell_NN number_NN ._. However_RB ,_, initiation_NN of_IN
          deoxycoformycin_NN (_( pentostatin_NN )_) therapy_NN resulted_VBD in_IN a_DT
          decrease_NN in_IN the_DT size_NN of_IN the_DT aberrant_NN CD_NNP 7_CD -_: dim_NN tumor_NN
          cluster_NN (_( as_RB well_RB as_IN decreases_NNS in_IN the_DT population_NN of_IN normal_JJ
          T-_NNP cells_NNS )_) ,_, consistent_JJ with_IN treatment_NN response_NN ._.
          In_IN 2_CD patients_NNS ,_, there_EX were_VBD changes_NNS in_IN the_DT phenotype_NN of_IN
          tumor_NN cells_NNS noted_VBD over_IN the_DT study_NN period_NN ._. In_IN one_CD case_NN ,_,
          large_JJ cell_NN transformation_NN of_IN tumor_NN cells_NNS was_VBD associated_VBN
          with_IN partial_JJ loss_NN of_IN surface_NN CD_NNP 3_CD ._. In_IN another_DT case_NN with_IN
          CD_NNP 4_CD -_: dim_NN and_CC CD_NNP 4_CD -_: negative_JJ tumor_NN cell_NN populations_NNS ,_,
          effective_JJ treatment_NN was_VBD associated_VBN with_IN selective_JJ loss_NN of_IN
          the_DT CD_NNP 4_CD -_: negative_JJ population_NN (_( data_NNS not_RB shown_VBN )_) ._.
        
      
      
        Discussion_NNP
        We_PRP examined_VBD the_DT flow_NN cytometry_NN findings_NNS in_IN involved_VBN PB_NNP
        samples_NNS from_IN 44_CD MF_NNP /_NN SS_NNP patients_NNS ,_, most_JJS of_IN who_WP had_VBD multiple_JJ
        sequential_NN involved_VBD PB_NNP samples_NNS ._. Using_VBG a_DT standard_JJ T-_NNP cell_NN
        cytometry_NN panel_NN ,_, we_PRP noted_VBD abnormal_JJ T-_NNP cell_NN populations_NNS
        showing_VBG one_CD or_CC more_JJR antigen_NN aberrancies_NNS in_IN 93_CD %_NN of_IN patients_NNS ._.
        In_IN 5_CD MF_NNP patients_NNS ,_, we_PRP noted_VBD multiple_JJ persistent_JJ
        phenotypically_RB abnormal_JJ T-_NNP cell_NN populations_NNS consistent_JJ with_IN
        clonal_NN heterogeneity_NN ._. We_PRP present_VB the_DT first_JJ report_NN on_IN the_DT
        stability_NN of_IN such_JJ abnormal_JJ immunophenotypes_NNS in_IN the_DT
        neoplastic_JJ T_NN cells_NNS of_IN SS_NNP /_NN MF_NNP ,_, over_IN disease_NN course_NN ._. Despite_IN
        varying_VBG treatments_NNS ,_, immunophenotypic_JJ aberrancies_NNS noted_VBD were_VBD
        maintained_VBN over_IN the_DT course_NN of_IN disease_NN in_IN 95_CD %_NN of_IN cases_NNS ,_,
        excluding_VBG common_JJ variations_NNS in_IN the_DT level_NN of_IN CD_NNP 7_CD expression_NN ._.
        These_DT findings_NNS support_VBP the_DT hypothesis_NNS that_IN these_DT abnormal_JJ
        T-_NNP cell_NN populations_NNS represent_VBP the_DT neoplastic_JJ clone_NN and_CC
        provide_VB strong_JJ support_NN for_IN the_DT use_NN of_IN flow_NN cytometry_NN in_IN
        routine_JJ monitoring_NN of_IN treatment_NN response_NN ._.
        Tumor-associated_NNP variation_NN in_IN one_CD or_CC several_JJ pan-_NN T_NN cell_NN
        antigens_NNS is_VBZ a_DT typical_JJ feature_NN of_IN neoplastic_JJ lymphocytes_NNS in_IN
        many_JJ T-_NNP cell_NN malignances_NNS and_CC has_VBZ been_VBN termed_VBN antigen_NN "_'' loss_NN "_''
        or_CC "_'' deletion_NN "_'' [_NN 7_CD ]_NN ._. Using_VBG immunohistochemistry_NN on_IN a_DT large_JJ
        bank_NN of_IN T-_NNP cell_NN lymphomas_NNS ,_, we_PRP have_VBP previously_RB noted_VBN a_DT
        frequency_NN of_IN such_JJ antigen_NN deletion_NN of_IN 18_CD %_NN for_IN CD_NNP 2_CD ,_, 26_CD %_NN for_IN
        CD_NNP 3_CD ,_, 30_CD %_NN for_IN CD_NNP 5_CD and_CC 68_CD %_NN for_IN CD_NNP 7_CD [_NN 8_CD ]_NN ._. Flow_NNP cytometric_JJ
        analysis_NN can_MD allow_VB a_DT more_RBR sensitive_JJ assessment_NN of_IN subtle_JJ
        variations_NNS in_IN the_DT levels_NNS of_IN surface_NN marker_NN expression_NN than_IN
        immunohistochemistry_NN [_NN 9_CD ]_NN ._. In_IN non-neoplastic_JJ T-_NNP cell_NN
        populations_NNS ,_, we_PRP noted_VBD relatively_RB narrow_JJ range_NN of_IN CD_NNP 3_CD ,_, CD_NNP 4_CD
        and_CC CD_NNP 5_CD expression_NN with_IN majority_NN of_IN cells_NNS clustering_VBG within_IN
        one_CD log_VB intensity_NN ._. In_IN contrast_NN ,_, the_DT aberrancies_NNS noted_VBD in_IN
        expression_NN in_IN T-_NNP cell_NN tumor_NN often_RB showed_VBD 2_CD -_: 3_CD log-fold_JJ
        intensity_NN differences_NNS from_IN the_DT normal_JJ populations_NNS [_NN 5_CD 9_CD 10_CD
        11_CD 12_CD ]_NN ._.
        Most_JJS routinely_RB assessed_VBN T-_NNP cell_NN diagnostic_JJ markers_NNS (_( e_SYM ._. g_SYM ._.
        TCR-α_NNP /_NN β_NN ,_, CD_NNP 3_CD ,_, CD_NNP 4_CD ,_, CD_NNP 8_CD and_CC CD_NNP 45_CD )_) are_VBP components_NNS of_IN the_DT
        antigen_NN receptor_NN complex_JJ and_CC are_VBP dynamically_RB regulated_VBN
        during_IN T-_NNP cell_NN maturation_NN and_CC activation_NN [_NN 13_CD ]_NN ._. In_IN a_DT
        subset_NN of_IN cases_NNS analyzed_VBD ,_, we_PRP noted_VBD that_DT surface_NN CD_NNP 3_CD levels_NNS
        frequently_RB correlated_JJ with_IN levels_NNS of_IN TCR-α_NNP /_NN β_NN ,_, but_CC that_IN CD_NNP 3_CD
        did_VBD not_RB always_RB correlate_VBP with_IN variations_NNS in_IN the_DT levels_NNS of_IN
        surface_NN CD_NNP 4_CD ._. We_PRP also_RB found_VBD variations_NNS in_IN MF_NNP /_NN SS_NNP tumor_NN cells_NNS
        in_IN the_DT expression_NN level_NN of_IN CD_NNP 45_CD ,_, a_DT phosphatase_NN that_WDT
        regulates_VBZ TCR_NNP activation_NN [_NN 14_CD ]_NN ._. The_DT finding_NN of_IN frequent_JJ
        variations_NNS in_IN the_DT levels_NNS of_IN these_DT TCR-complex_NNP proteins_NNS in_IN
        tumors_NNS is_VBZ intriguing_JJ and_CC suggests_VBZ abnormal_JJ regulation_NN or_CC
        formation_NN of_IN the_DT TCR_NNP complex_JJ in_IN some_DT tumor_NN cells_NNS ._. This_DT
        could_MD be_VB lead_VBN to_TO dysregulated_JJ TCR_NNP signaling_VBG effecting_VBG
        growth_NN regulation_NN ._.
        In_IN previous_JJ studies_NNS ,_, others_NNS and_CC we_PRP have_VBP noted_VBN that_IN MF_NNP /_NN SS_NNP
        tumor_NN cells_NNS frequently_RB lacked_VBD CD_NNP 26_CD ,_, and_CC that_IN this_DT finding_VBG
        was_VBD helpful_JJ in_IN identifying_VBG the_DT tumor_NN cell_NN population_NN [_NN 4_CD 15_CD
        ]_NN ._. In_IN this_DT larger_JJR longitudinal_NN series_NN ,_, we_PRP confirm_VBP these_DT
        findings_NNS and_CC noted_VBD that_IN tumor_NN cells_NNS showed_VBD a_DT consistent_JJ
        pattern_NN of_IN CD_NNP 26_CD loss_NN over_IN the_DT course_NN of_IN disease_NN ._. The_DT stable_JJ
        loss_NN of_IN expression_NN of_IN CD_NNP 26_CD ,_, a_DT T-_NNP cell_NN activation_NN marker_NN ,_, in_IN
        MF_NNP /_NN SS_NNP suggests_VBZ that_IN this_DT activation_NN pathway_NN may_MD be_VB
        nonfunctional_NN in_IN most_JJS MF_NNP /_NN SS_NNP tumors_NNS ._. CD_NNP 26_CD is_VBZ an_DT ectoenzyme_NN ,_,
        which_WDT delivers_VBZ a_DT costimulatory_NN signal_NN in_IN T-_NNP cells_NNS ;_: its_PRP$
        expression_NN is_VBZ upregulated_JJ on_IN T-_NNP cells_NNS in_IN response_NN to_TO
        mitogenic_JJ signals_NNS and_CC downregulated_JJ through_IN interaction_NN
        with_IN the_DT insulin-like_JJ growth_NN factor_NN II_NNP receptor_NN [_NN 16_CD ]_NN ._.
        The_DT consequence_NN of_IN CD_NNP 26_CD loss_NN is_VBZ unclear_JJ ;_: CD_NNP 26_CD modulates_NNS the_DT
        action_NN of_IN many_JJ molecules_NNS including_VBG the_DT chemotactic_JJ activity_NN
        of_IN some_DT chemokine_NN important_JJ for_IN T-_NNP cell_NN migration_NN to_TO skin_NN [_NN
        17_CD 18_CD ]_NN ._.
        In_IN contrast_NN ,_, we_PRP noted_VBD that_IN CD_NNP 7_CD expression_NN was_VBD frequently_RB
        modulated_JJ in_IN tumor_NN cells_NNS over_IN the_DT disease_NN course_NN ._. Several_JJ
        previous_JJ studies_NNS have_VBP demonstrated_VBN that_IN CD_NNP 7_CD loss_NN is_VBZ not_RB a_DT
        predictable_JJ marker_NN for_IN detection_NN of_IN MF_NNP /_NN SS_NNP cells_NNS ,_, as_IN its_PRP$
        expression_NN is_VBZ variable_JJ in_IN this_DT tumor_NN type_NN [_NN 15_CD 19_CD ]_NN ._.
        Although_IN there_EX is_VBZ data_NNS to_TO suggest_VB that_IN CD_NNP 7_CD -_: negative_JJ T-_NNP cells_NNS
        may_MD represent_VB a_DT distinct_JJ differentiation_NN pathway_NN in_IN normal_JJ
        and_CC neoplastic_JJ helper_NN T_NN cells_NNS ,_, [_NN 20_CD 21_CD ]_NN the_DT variable_JJ
        expression_NN of_IN CD_NNP 7_CD in_IN MF_NNP /_NN SS_NNP that_IN we_PRP have_VBP observed_VBN suggests_VBZ
        that_IN this_DT marker_NN may_MD be_VB highly_RB modulated_JJ by_IN tumor_NN
        microenvironment_NN and_CC /_NN or_CC treatment_NN ._.
        Identification_NNP of_IN a_DT stable_JJ tumor-associated_JJ
        immunophenotype_NN in_IN MF_NNP /_NN SS_NNP allows_VBZ tumor_NN cell_NN quantification_NN
        to_TO assess_VB response_NN to_TO therapy_NN ._. Cluster_NNP analysis_NN of_IN abnormal_JJ
        flow_NN cytometric_JJ immunophenotype_NN is_VBZ more_RBR reliable_JJ and_CC easier_JJR
        to_TO compare_VB over_IN time_NN than_IN morphologic_JJ analysis_NN ,_, and_CC can_MD
        detect_VB PB_NNP involvement_NN in_IN a_DT small_JJ number_NN of_IN cases_NNS without_IN
        easily_RB identifiable_JJ Sezary_NNP cells_NNS [_NN 12_CD ]_NN ._. Routine_NNP flow_NN
        cytometric_JJ profiling_VBG is_VBZ also_RB not_RB as_RB technically_RB demanding_VBG
        as_IN molecular_JJ monitoring_NN [_NN 22_CD 23_CD ]_NN or_CC electron_NN microscopy_NN ._.
        Such_JJ a_DT separation_NN of_IN tumor_NN from_IN normal_JJ T-_NNP cells_NNS is_VBZ also_RB
        important_JJ in_IN assessing_VBG the_DT effects_NNS of_IN therapies_NNS on_IN normal_JJ
        leukocytes_NNS ._.
        In_IN conclusion_NN ,_, we_PRP found_VBD that_IN the_DT absence_NN of_IN CD_NNP 26_CD and_CC
        other_JJ aberrant_NN surface_NN expression_NN of_IN T_NN cell-associated_JJ
        markers_NNS allowed_VBD identification_NN of_IN a_DT discrete_JJ ,_, quantifiable_JJ
        population_NN in_IN nearly_RB all_DT MF_NNP /_NN SS_NNP patients_NNS with_IN PB_NNP tumor_NN
        cells_NNS ._. Immunophenotypic_NNP aberrancies_NNS are_VBP maintained_VBN
        consistently_RB over_IN the_DT course_NN of_IN disease_NN and_CC can_MD be_VB used_VBN to_TO
        monitor_VB tumor_NN response_NN to_TO therapy_NN ._.
      
    
  
